Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
复制标题
DOI：
10.1136/ard.2010.139725
复制
发表时间：
2011-05-01
影响因子：
27.4
通讯作者：
Rubbert-Roth, A.
中科院分区：
文献类型：
--
作者：
Burmester, Gerd R.;Feist, E.;Rubbert-Roth, A.
目的 为了在德国接近现实医疗保健的环境中确认白细胞介素 6 受体拮抗剂托珠单抗 (tocilizumab) 对类风湿性关节炎 (RA) 患者的有效性和安全性。方法进行了一项多中心开放标签 IIIb 期研究。尽管既往使用了疾病缓解抗风湿药物 (DMARD)，但 28 关节疾病活动评分 (DAS28) > 3.2 的活动性 RA 患者每 4 周接受 8 mg/kg 托珠单抗治疗。主要终点是达到 LDAS 的患者比例
Objectives To confirm the effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab in patients with rheumatoid arthritis (RA) in a setting close to real-life medical care in Germany.Methods A multicentre open-label phase IIIb study was undertaken. Patients with active RA with a 28-joint Disease Activity Score (DAS28) > 3.2 despite previous disease-modifying antirheumatic drugs (DMARDs) were treated with tocilizumab 8 mg/kg every 4 weeks. The primary end point was the proportion of patients achieving LDAS